Gliomatosis cerebri history and symptoms
|
Gliomatosis cerebri Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gliomatosis cerebri history and symptoms On the Web |
|
American Roentgen Ray Society Images of Gliomatosis cerebri history and symptoms |
|
Risk calculators and risk factors for Gliomatosis cerebri history and symptoms |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
When evaluating a patient for gliomatosis cerebri, you should take a detailed history of the presenting symptom (onset, duration, and progression), other associated symptoms, and a thorough family and past medical history review. Other specific areas of focus when obtaining the history include review of common associated conditions such as neurofibromatosis type 1.[1] Symptoms of gliomatosis cerebri include headache, nausea, vomiting, seizure, loss of balance, memory loss, personality changes, cognitive problems, confusion, diplopia, difficulty in swallowing, difficulty in speech, motor weakness, and facial numbness.[2]
History
When evaluating a patient for gliomatosis cerebri, you should take a detailed history of the presenting symptom (onset, duration, and progression), other associated symptoms, and a thorough family and past medical history review. Other specific areas of focus when obtaining the history include:[1]
- Review of common associated conditions such as neurofibromatosis type 1
Symptoms
Symptoms of gliomatosis cerebri include:[2]
- Headache
- Nausea
- Vomiting
- Seizure
- Loss of balance
- Memory loss
- Personality changes
- Cognitive problems
- Confusion
- Diplopia
- Difficulty in swallowing
- Difficulty in speech
- Motor weakness
- Facial numbness
References
- ↑ 1.0 1.1 Koszyca B, Moore L, Byard RW (1993). "Lethal manifestations of neurofibromatosis type 1 in childhood". Pediatr Pathol. 13 (5): 573–81. PMID 8247955.
- ↑ 2.0 2.1 Buis DR, van der Valk P, De Witt Hamer PC (2012). "Subcutaneous tumor seeding after biopsy in gliomatosis cerebri". J Neurooncol. 106 (2): 431–5. doi:10.1007/s11060-011-0678-2. PMC 3230756. PMID 21837541.